Vaccine Journal

Overview
Identity
View All

publication venue for

Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey.. 42:1704-1713. 2024
Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in the United States in late 2023.. 41:7503-7514. 2023
Assessing vaccine hesitancy and support for vaccination requirements for pets and potential Spillovers from humans.. 41:7322-7332. 2023
Imperfect messengers? An analysis of vaccine confidence among primary care physicians.. 40:2588-2603. 2022
Childhood immunization during the COVID-19 pandemic in Texas.. 39:3333-3337. 2021
Who receives influenza vaccinations at the Pharmacy? An analysis of the Texas Behavioral Risk Factor Surveillance System.. 39:2857-2866. 2021
Joining the herd? U.S. public opinion and vaccination requirements across educational settings during the COVID-19 pandemic.. 39:2375-2385. 2021
Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MvjbR strain in goats.. 39:617-625. 2021
Vaccination against coronaviruses in domestic animals.. 38:5123-5130. 2020
Global assessment of national mandatory vaccination policies and consequences of non-compliance.. 38:7865-7873. 2020
Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model.. 38:2340-2349. 2020
Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody.. 38:298-308. 2020
PNAG-specific equine IgG1 mediates significantly greater opsonization and killing of Prescottella equi (formerly Rhodococcus equi) than does IgG4/7.. 37:1142-1150. 2019
Enhanced protective efficacy of Borrelia burgdorferi BB0172 derived-peptide based vaccine to control Lyme disease.. 37:5596-5606. 2019
Development of a synthetic Vi polysaccharide vaccine for typhoid fever.. 35:7121-7126. 2017
Development of a novel dual-domain nanoparticle antigen construct for universal influenza vaccine.. 35:7026-7032. 2017
Antibody titers to vaccination are not predictive of level of protection against a BVDV type 1b challenge in Bos indicus - Bos taurus steers.. 34:5053-5059. 2016
Infectivity of attenuated poxvirus vaccine vectors and immunogenicity of a raccoonpox vectored rabies vaccine in the Brazilian Free-tailed bat (Tadarida brasiliensis).. 34:5352-5358. 2016
Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses.. 33:2881-2886. 2015
Altered host immune responses to membrane vesicles from Salmonella and Gram-negative pathogens.. 33:5012-5019. 2015
Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.. 32:2756-2762. 2014
Supercritical fluid extraction provides an enhancement to the immune response for orally-delivered hepatitis B surface antigen.. 32:1240-1246. 2014
Immunotherapeutics to prevent the replication of Brucella in a treatment failure mouse model.. 32:918-923. 2014
New attenuated vaccine against columnaris disease in fish: choosing the right parental strain is critical for vaccine efficacy.. 31:5276-5280. 2013
Dengue dynamics and vaccine cost-effectiveness in Brazil.. 31:3957-3961. 2013
Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty.. 31:3079-3089. 2013
Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep.. 31:559-565. 2013
Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves.. 31:4988-4994. 2013
Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen.. 30:2937-2942. 2012
Cell culture attenuation eliminates rMd5Meq-induced bursal and thymic atrophy and renders the mutant virus as an effective and safe vaccine against Marek's disease.. 30:5151-5158. 2012
Measuring bovine viral diarrhea virus vaccine response: using a commercially available ELISA as a surrogate for serum neutralization assays.. 30:6559-6563. 2012
Enhancing the role of veterinary vaccines reducing zoonotic diseases of humans: linking systems biology with vaccine development.. 29:7197-7206. 2011
Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.. 29:5221-5231. 2011
Development of DIVA (differentiation of infected from vaccinated animals) vaccines utilizing heterologous NA and NS1 protein strategies for the control of triple reassortant H3N2 influenza in turkeys.. 29:7966-7974. 2011
Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challenge.. 29:784-794. 2011
Characterization and evaluation of avian influenza NS1 mutant virus as a potential live and killed DIVA (differentiating between infected and vaccinated animals) vaccine for chickens.. 28:2388-2396. 2010
Comparative evaluation of vaccine efficacy of recombinant Marek's disease virus vaccine lacking Meq oncogene in commercial chickens.. 28:1294-1299. 2010
Brucellosis: the case for live, attenuated vaccines.. 27 Suppl 4:D40-D43. 2009
A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection.. 27:4209-4218. 2009
Basal and stimulus-induced cytokine expression is selectively impaired in peripheral blood mononuclear cells of newborn foals.. 27:674-683. 2009
Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV.. 26:1887-1892. 2008
Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis.. 24:5169-5177. 2006
Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine.. 24:6175-6186. 2006
Multicomponent Lyme vaccine: three is not a crowd.. 23:3687-3696. 2005
A serine proteinase inhibitor (serpin) from ixodid tick Haemaphysalis longicornis; cloning and preliminary assessment of its suitability as a candidate for a tick vaccine.. 21:2844-2851. 2003
Plant-based vaccines: unique advantages.. 19:2742-2748. 2001
cDNA cloning, characterization and vaccine effect analysis of Haemaphysalis longicornis tick saliva proteins.. 19:4287-4296. 2001
Absence of shedding of two B. abortus strains in goats after vaccination with live vaccines.. 18:3018-3020. 2000
Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide.. 16:76-82. 1998
Antigen dependent adjuvant activity of a polydispersed beta-(1,4)-linked acetylated mannan (acemannan).. 10:551-557. 1992